EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Between Rigor and Relevance: Why the EU HTA Guidelines on Indirect Comparisons Miss the Mark

Samuel Aballéa iD, Mondher Toumi, Piotr Wojciechowski iD, Emilie Clay, Bruno Falissard, Steven Simoens iD, Pascal Auquier, Stefano Capri iD, Renato Bernardini, Joerg Ruof iD, Frank-Ulrich Fricke, Oriol Sola Morales und 1 weitere

Journal of Market Access & Health Policy · 07.05.2026 · 14 (2) · 30

DOI: 10.3390/jmahp14020030 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Market Access & Health Policy, online erschienen am 07.05.2026. Verfasst von Samuel Aballéa und 12 weiteren Autor:innen. Beteiligte Einrichtung: InovIntell, 3023 GJ Rotterdam, The Netherlands. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Indirect treatment comparisons (ITCs) are essential in the context of joint clinical assessments (JCAs) under Regulation (European Union [EU]) 2021/2282, bridging evidence gaps where head-to-head data are lacking and enabling assessment across diverse national patient, intervention, comparator, and outcome (PICO) requirements. This paper critically reviews the EU Health Technology Assessment Coordination Group’s (HTACG) guidelines on direct and indirect comparisons, with particular focus on ITCs. While the guidelines promote transparency and rigorous evaluation of assumptions, they adopt a restrictive stance on assumption violations, the use of unanchored comparisons, and population-adjusted methods such as matching-adjusted indirect comparisons (MAIC) and simulated treatment comparisons (STC). The guidance shows limited support for Bayesian methods and undervalues meta-regression in favor of subgroup analyses. Operational implications for health technology developers (HTDs) are substantial, including new requirements for dual systematic reviews, multiple network structures, and shifted null hypothesis testing. Moreover, the guidelines effectively dissuade the use of non-randomized comparisons in rare or rapidly evolving indications and may inadvertently hinder access to effective treatments. Emerging practices such as external control arms (ECA) or target trial emulation are underdeveloped. Notably, there is no indication that the guidelines are grounded in systematic methodological validation studies. As JCAs evolve, greater methodological flexibility, empirical grounding, and clear operational guidance will be essential. Refining the guidelines along these principles would enhance their practical utility, mitigate intrinsic assessment variability, support consistent assessments across Member States (MS), and ultimately improve patient access to innovative therapies.

Schlagwörter

Stichwörter der Autor:innen

European Union health technology assessment (EU HTA)indirect treatment comparison (ITC)joint clinical assessment (JCA)matching-adjusted indirect comparison (MAIC)network meta-analysis (NMA)population-adjusted indirect comparisons (PAICs)simulated treatment comparison (STC)

Autor:innen und Institutionen

  • InovIntell, 3023 GJ Rotterdam, The Netherlands.
  • CEReSS/UR3279-Health Services Research and Quality of Life Center, Aix-Marseille University, 13385 Marseille, France.
  • Clever-Access, Wadowicka 8A, 30-415 Kraków, Poland.
  • Clever-Access, 75008 Paris, France.
  • CESP, INSERM U1018, Université Paris-Saclay, 94800 Villejuif, France.
  • Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.

ORCID-Profile: Samuel Aballéa, Piotr Wojciechowski, Steven Simoens, Stefano Capri, Joerg Ruof, Laurent Boyer

Zitieren

APA

Aballéa, S., Toumi, M., Wojciechowski, P., Clay, E., Falissard, B., Simoens, S., Auquier, P., Capri, S., Bernardini, R., Ruof, J., Fricke, F. U., Morales, O. S., & Boyer, L. (2026). Between Rigor and Relevance: Why the EU HTA Guidelines on Indirect Comparisons Miss the Mark. Journal of Market Access & Health Policy, 14(2), 30. https://doi.org/10.3390/jmahp14020030

Vancouver

Aballéa S, Toumi M, Wojciechowski P, Clay E, Falissard B, Simoens S, et al. Between Rigor and Relevance: Why the EU HTA Guidelines on Indirect Comparisons Miss the Mark. Journal of Market Access & Health Policy. 2026;14(2):30. doi:10.3390/jmahp14020030

BibTeX
@article{Aballa2026,
  author = {Aballéa, Samuel and Toumi, Mondher and Wojciechowski, Piotr and Clay, Emilie and Falissard, Bruno and Simoens, Steven and Auquier, Pascal and Capri, Stefano and Bernardini, Renato and Ruof, Joerg and Fricke, Frank-Ulrich and Morales, Oriol Sola and Boyer, Laurent},
  title = {Between Rigor and Relevance: Why the EU HTA Guidelines on Indirect Comparisons Miss the Mark},
  journal = {Journal of Market Access & Health Policy},
  year = {2026},
  volume = {14},
  number = {2},
  pages = {30},
  doi = {10.3390/jmahp14020030}
}
Kostenlos starten →